Market News
Monday, December 19, 2016
BRIEF-Pharnext completes patient enrollment in Pivotal Phase 3 trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1a
* Pharnext completes patient enrollment in international
pivotal phase 3 trial of PXT3003 for Charcot-Marie-Tooth Disease
Type 1a
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment